INTRODUCTION {#SEC1}
============

*Mycobacterium tuberculosis* is the main causative pathogen of tuberculosis and the second greatest killer after the Human Immunodeficiency Virus (HIV) among single infectious agents ([@B1]). *M. tuberculosis* causes disease by adapting to the host immune response using dedicated regulatory systems that include the White B-like (Wbl) family proteins. Wbl proteins contain a \[4Fe--4S\] cluster, were first identified in *Streptomyces coelicolor*, and are widely distributed in actinobacteria ([@B2],[@B3]). Seven Wbl proteins are found in *M. tuberculosis*, and they play versatile roles in diverse biological processes including redox homeostasis, cell division, nutrition starvation and antibiotic resistance ([@B4]).

Structural and functional analyses indicate that *M. tuberculosis* Wbl proteins are monomeric transcription factors with three conserved motifs ([@B4]): (*i*) a \[4Fe--4S\] cluster binding motif consisting of four cysteines in the N-terminus, (*ii*) a DNA binding motif (also known as AT-hook) in the C-terminus and (*iii*) an intervening Gly-rich motif (β-turn) that links the two functional domains. *M. tuberculosis* Wbl proteins interact with the primary sigma factor σ^A^ of the RNA polymerase (RNAP) holoenzyme in their \[4Fe--4S\] cluster-bound (holo-) form, but not in their cluster-free (apo-) form ([@B7],[@B8]). σ^A^ is a member of the σ^70^-family primary sigma factors possessing four conserved regions (region 1--4), of which region 4 (σ^70^~4~) recognizes the −35 element and is a highly conserved hub for direct interaction with many transcription factors including the *M. tuberculosis* Wbl proteins ([@B7],[@B9],[@B10]). Two Wbl members (WhiB3 and WhiB7) have been shown to require interaction with σ^A^~4~ to activate transcription ([@B7],[@B11],[@B12]).

Among the *M. tuberculosis* Wbl proteins, WhiB1 is of particular interest because it is essential for cell growth and it is suggested to have a role in the initiation of dormancy in response to nitric oxide (NO) ([@B6]). NO is a potent antimicrobial chemical produced by hosts to combat tuberculosis infection ([@B13],[@B14]). Consequently, the transcription factors in the defense system of *M. tuberculosis* that swiftly sense and respond to NO are critical for the survival and pathogenesis of the bacterium. The \[4Fe--4S\] cluster in WhiB1 is highly reactive to NO over O~2~ ([@B15],[@B16]), making it a specific NO sensor in aerobic bacteria. NO disrupts the WhiB1 \[4Fe--4S\] cluster by initially forming a \[Fe-S\] cluster--NO complex, and eventually resulting in cluster degradation and formation of apo-WhiB1 ([@B15]). Binding of WhiB1 to σ^A^ significantly decreases the O~2~ reactivity of the \[4Fe--4S\] cluster in the WhiB1:σ^A^ complex, which is reportedly stable under aerobic conditions for two weeks while retaining high reactivity to NO ([@B8]). Upon exposure to NO both *in vitro* and in *Escherichia coli*, the WhiB1:σ^A^ complex was observed to rapidly react with NO and disassociate ([@B8]). This observation indicates a potential role of WhiB1 as a NO sensor and regulator in mycobacteria considering that the WhiB1:σ^A^ complex is reactive to NO in the presence of the native NO-sensing and detoxification system in *E. coli* ([@B17]). The molecular basis for the O~2~ stability of the \[4Fe--4S\] cluster in the WhiB1:σ^A^ complex is unknown because the structure of the complex has not been determined.

Both NO-treated holo-WhiB1 and apo-WhiB1, but not holo-WhiB1, have been shown to bind to and repress at least two essential genes: *groEL2*, encoding a chaperonin; and *whiB1* itself ([@B6],[@B18]). The positively charged residues in the C-terminal DNA binding motif of apo-WhiB1, including Lys72, Arg73, Arg74, Lys79 and Arg81, are required for DNA binding ([@B19]). For this reason, WhiB1 was defined as a transcriptional repressor in the past ([@B6]), while the active form of WhiB1 that supports active mycobacterial growth remains elusive. Based on its interaction with σ^A^~4~, holo-WhiB1 has been proposed to activate gene expression using a canonical mechanism utilized by Class II transcription activators such as the cyclic AMP receptor protein (CRP) and the fumarate and nitrate reduction regulatory protein (FNR) ([@B10],[@B20]). However, holo-WhiB1 possesses characteristics that are different from previously characterized Class II transcription activators. First, WhiB1 is a monomeric transcription factor with a single DNA binding motif, while canonical Class II transcription activators are either homodimers or contain multiple DNA binding motifs that confer high specificity and affinity for target DNA ([@B10],[@B23]). Second, holo-WhiB1 does not bind to its own promoter and no target gene of holo-WhiB1 has been identified thus far ([@B6]), while σ^70^~4~-binding transcription activators are typically self-regulated, activating gene expression by binding to specific promoter sequences and recruiting RNAP to the target genes ([@B10],[@B25]). An in-depth mechanistic understanding of transcriptional regulation by WhiB1 requires atomic-resolution structural information showing how holo-WhiB1 interacts with σ^A^~4~. An NMR structure of free holo-WhiB1 has been reported ([@B8]), but there is no 3D structural information available for σ^A^-bound WhiB1 or any other Wbl proteins.

In the course of defining the molecular mechanism of holo-WhiB1 in σ^A^~4~-dependent transcriptional regulation, we solved a crystal structure of holo-WhiB1 in complex with the C-terminal domain of σ^A^ (σ^A^~CTD~) containing the intact σ^A^~4~ region. Our structural analysis reveals that hydrophobic residues unexpectedly dominate the interaction between holo-WhiB1 and σ^A^. This is distinctly different from previously characterized Class II transcription activators, which typically interact loosely with region 4 of σ^70^-family primary sigma factors through polar residues on the surface ([@B11],[@B12],[@B26],[@B27]). *In vitro*, the observed transcription repression by holo-WhiB1 via interaction with σ^A^~4~ further supports the hypothesis that WhiB1 regulates gene expression in a manner distinct from the canonical transcription activation by σ^A^~4~-bound Class II activators. In addition, the local protein environment of the Fe−S cluster in the WhiB1:σ^A^~CTD~ complex explains how the complex formation renders this typically O~2~-labile cluster into a remarkably O~2~-stable \[4Fe--4S\] cluster that can sense NO in aerobic bacteria.

MATERIALS AND METHODS {#SEC2}
=====================

Bacterial strains and growth media {#SEC2-1}
----------------------------------

The bacterial strains and plasmids used in this study are listed in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. All the *E. coli* strains used for cloning and protein over-expression were grown in Luria--Bertani (LB) media supplemented with suitable antibiotics as needed at 37 °C with shaking at 200 rpm, unless otherwise specified.

*Mycobacterium smegmatis* MC^2^ 155 (*M. smegmatis*) and the related *whiB1* mutants generated in this study were grown in either Middlebrook 7H9 broth or on 7H10 agar (BD Difco^TM^) supplemented with 10% (v/v) ADC (2% dextrose, 5% bovine serum albumin, 0.85% NaCl and 0.003% catalase), 0.2% (v/v) glycerol, 0.05% (v/v) Tween 80 (Sigma) and suitable antibiotics as needed.

Creation of a conditional *whiB1* knockout mutant in *M. smegmatis* {#SEC2-2}
-------------------------------------------------------------------

The *whiB1 (MSMEG_1919)* knockout mutant in *M. smegmatis* was generated using homologous recombination-based in-frame unmarked deletion as previously described ([@B28]). Briefly, a 844-bp DNA fragment upstream of *whiB1* and a 1135-bp DNA fragment downstream of *whiB1* were amplified by PCR from the genomic DNA of *M. smegmatis* and cloned into pUC-Zeo flanking the zeocin resistance gene to construct the recombinant plasmid pUC-Zeo+MsmwhiB1LR. After confirming the construct by DNA sequencing, a linear recombinant DNA fragment was prepared by double digestion of pUC-Zeo+MsmwhiB1LR with KpnI and HindIII. The resulting linear DNA fragment was electroporated into an *M. smegmatis* strain containing the helper plasmid pJV53-GFP to allow the expression of recombination proteins gp60 and gp61 of mycobacteriophage Che9c ([@B29]). Transformants were selected on 7H10 agar plates supplemented with 25 μg/ml kanamycin and 50 μg/ml zeocin. As reported for *M. tuberculosis* ([@B6]), no viable *whiB1* deletion mutants were obtained after multiple attempts, although single crossover was observed.

To confirm that *whiB1* is essential in *M. smegmatis*, we created a conditional *whiB1* knockout mutant as shown in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}. For this purpose, the DNA fragment containing the 3FLAG-tagged *whiB1* gene with its flanking sequences (1159 bp upstream and 638 bp downstream of *whiB1*, respectively) was cloned into the integration plasmid pKW08-Lx-Int ([@B30]). The resulting plasmid pKW08 + 3FLAGwhiB1LR was transformed and integrated in the genome of *M. smegmatis* to obtain a complementary copy of *whiB1* under its native promoter in the genome of *M. smegmatis*. This strain was used for subsequent deletion of *whiB1* at its native location as described above. Several colonies from the screening plates were streaked on 7H10 agar plates without antibiotics to facilitate excision of the zeocin cassette. The conditional *whiB1* knockout mutant from the resulting colonies was verified by PCR and further confirmed by DNA sequencing ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

Site-directed mutagenesis of *whiB1* in *M. smegmatis* {#SEC2-3}
------------------------------------------------------

To generate site-directed *whiB1* mutants in *M. smegmatis*, a template plasmid pUC-Hyg+MsmwhiB1SDM was first constructed with a 612-bp DNA fragment containing the *whiB1* gene and its upstream DNA flanking the left arm, and a 1135-bp DNA fragment downstream of *whiB1* flanking the right arm of the hygromycin resistance gene, respectively. Desired single point mutations of *whiB1* in pUC-Hyg+Msm-whiB1SDM were constructed using Q5^®^ Site-Directed Mutagenesis Kit (New England Biolabs) according to the manufacturer\'s instructions and confirmed by DNA sequencing. Linear recombinant DNA fragments were then prepared from the resulting plasmids by double digestion with KpnI and HindIII, and electroporated into an *M. smegmatis* strain containing the helper plasmid pJV53-GFP. The homologous recombination procedures for generating site-directed *whiB1* mutants were similar to those used in creating the *whiB1* deletion mutant, as previously described ([@B28]). The resulting *whiB1* mutants were verified by PCR and further confirmed by DNA sequencing.

Plasmid construction for protein over-expression in *E. coli* {#SEC2-4}
-------------------------------------------------------------

The DNA sequences encoding the wildtype WhiB1 (Rv3219, 1--84 aa) and the C-terminal domain of σ^A^ (Rv2703) containing the C-terminal residues 359--528 of the protein (denoted σ^A^~C170~) were amplified by PCR from *M. tuberculosis* H37Rv genomic DNA (a gift from Dr. Midori Kato-Maeda\'s group at the University of California, San Francisco). The *whiB1* gene was cloned into pET19b and the *σ^A^~C170~* gene was cloned into pCDF-1b to express His~10~-WhiB1 and His~6~-σ^A^~C170~, respectively. These plasmids were then further modified for expressing the truncated and mutant proteins used for crystallization and pull-down assays.

For preparing tagless WhiB1 used in *in vitro* pull-down assays and *in vitro* transcription, the *whiB1* gene was cloned into pETDuet-His~6~-SUMO vector (modified from pETDuet). For co-expression and purification with His~6~-σ^A^~C170~, the *whiB1* gene was cloned into the pET28b vector to express the tagless WhiB1 wildtype and mutant proteins. The pET21b-MtbWhiB1--76 and pET28b-6HisMtbσ^A^~C112~ plasmids were used for over-expressing and purifying the WhiB1:σ^A^~C112~ complex used for crystallization.

All the plasmids were confirmed by DNA sequencing before being transformed into *E. coli* BL21-Gold (DE3) strain for protein expression.

General procedures for protein expression, purification and analysis {#SEC2-5}
--------------------------------------------------------------------

Over-expression of proteins for structural and biochemical studies was done in *E. coli* BL21-Gold (DE3). Protein expression was induced by adding 100 μM isopropyl *β*-[d]{.smallcaps}-thiogalactopyranoside (IPTG, Sigma-Aldrich) to the cell culture at 16 °C for 12--15 h grown in Terrific Broth. For over-expression of proteins containing a \[4Fe--4S\] cluster, 100 μM ferric ammonium sulfate was added to the cell culture before induction. Cells were collected by centrifugation and kept at −80 °C for storage.

Affinity purification of His-tagged proteins containing WhiB1 (wildtype and mutants) was carried out using a HisTrap HP column (GE Healthcare Life Sciences) at room temperature either in an anaerobic chamber (Coy Lab) or under a customized Schlenk Line, unless otherwise specified. All the buffers used for protein purification were thoroughly degassed under the Schlenk Line and supplemented with 1 mM 1,4-dithiothreitol (DTT) immediately before use. Purification of His~6~-σ^A^ or His~6~-σ^A^~C170~ was performed at 4°C under aerobic conditions to minimize degradation. Phenylmethanesulfonyl fluoride (PMSF at 1 mM, Sigma-Aldrich) and the Roche Protease Inhibitor Cocktail (at 1 tablet/100 ml buffer) were added to the lysis buffer to reduce degradation of target proteins. Imidazole in the eluted fractions was removed by passing through either a desalting column or a Superdex 200 column (GE Healthcare Life Sciences). Samples after each step of purification were analyzed by SDS-PAGE and by UV-Visible (UV-Vis) spectroscopy. Unless otherwise specified, the final purified proteins in 50 mM Tris−HCl, pH 8.0, 100 mM NaCl, 1mM DTT were stored in liquid nitrogen until use.

The selenomethionine (SeMet)-substituted WhiB1:σ^A^~C112~ protein used for single wavelength anomalous diffraction (SAD) phasing was expressed in *E. coli* BL21-Gold (DE3) by the metabolic inhibition method as previously described ([@B31]) and purified by Ni^2+^-affinity chromatography and gel filtration as described above.

For preparing tagless WhiB1 used in the pull-down assays and *in vitro* transcription, the SUMO tag was removed from the purified His~6~-SUMO-WhiB1 by the SUMO protease Ulp1 (Thermo Fisher Scientific). The resulting sample was passed through HisTrap HP column to remove undigested protein and Ulp1, and further purified by gel filtration.

Expression and purification of the *M. tuberculosis* RNA polymerase core enzyme from *E. coli* was carried out as previously described ([@B32]). The plasmid used for expression of the *M. tuberculosis* RNA polymerase core enzyme was received from Dr Robert Landick\'s group at the University of Wisconsin--Madison and used without any modification. *M. tuberculosis* RNA polymerase holoenzyme was prepared by mixing the purified *M. tuberculosis* RNA polymerase core enzyme with excess His~6~-σ^A^, and passing the mixture through a gel filtration column (Superose 6 increase 10/300 GL, GE Healthcare Life Sciences) to remove unbound His~6~-σ^A^.

UV-Vis spectra of the purified proteins were recorded using an HP 8452a diode array UV-Vis spectrophotometer (Agilent Technologies Inc.). Protein concentrations were estimated by the Pierce Bradford Assay Kit (Thermo Fisher Scientific) and by the absorption at 280 nm. The absorption at 410 nm, which is characteristic of proteins containing \[4Fe--4S\]^2+^ clusters ([@B15],[@B33]), was used to estimate the occupancy of the \[4Fe--4S\]^2+^ cluster in the protein samples containing WhiB1.

Western blot analysis of 3FLAG-tagged proteins was detected by chemiluminescence using mouse anti-FLAG M2 antibody (Sigma) as the primary antibody and the horseradish peroxidase-coupled goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories) as the secondary antibody.

Crystallization {#SEC2-6}
---------------

Initial crystallization screens of the WhiB1:σ^A^~C112~ complex were carried out at 18°C in a Coy anaerobic chamber using the sitting-drop vapor diffusion method, followed by optimization of the crystallization hits. High-quality crystals were obtained by mixing 1 μl of WhiB1:σ^A^~C112~ at 70 mg/ml with an equal volume of the reservoir solution containing 100 mM Bis-Tris pH 5.5, 200 mM MgCl~2~ and 25% (w/v) PEG3350. Crystals of the SeMet-substituted WhiB1:σ^A^~C112~ were produced under the same conditions. All the crystals were briefly soaked in the reservoir solution supplemented with 20% glycerol for cryoprotection before flash-cooling in liquid nitrogen.

The σ^A^~C112~ protein in the complex was partially degraded during the crystallization process based on SDS-PAGE analysis and peptide identification by mass spectrometry. In the high-quality single crystals used for X-ray crystallography, partially degraded σ^A^~C112~ showed a similar apparent size as WhiB1 on the SDS-PAGE gel ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

X-ray crystallographic data collection, structural determination and analysis {#SEC2-7}
-----------------------------------------------------------------------------

X-ray diffraction data were collected at the beamlines 9-2 and 12-2 of the Stanford Synchrotron Radiation Lightsource from single crystals maintained at 100 K using a 6M Pixel Array Detector. The SAD data were collected from a single SeMet-substituted WhiB1:σ^A^~C112~ crystal at the Se K-edge absorption peak (12,679 eV). The diffraction data were indexed, integrated and scaled with either HKL2000 or XDS ([@B34],[@B35]). Two different crystal forms, *C*222~1~ and *P*2~1~, were found in the crystals produced from different batches of crystallization.

Experimental phases were determined by SAD with Phenix.Autosol ([@B36]), using the SeMet-substituted WhiB1:σ^A^~C112~ diffraction data up to 2.1 Å resolution. Since no crystal of the native WhiB1:σ^A^~C112~ diffracted better than 2.3 Å, the same dataset used for experiment phasing was used for structure refinement with a resolution cutoff extended to 1.85 Å considering the high multiplicity of the data and the CC~1/2~ of 0.882 in the highest resolution shell.

Model building and structure refinement were carried out using COOT and Phenix ([@B37],[@B38]). Two copies of the WhiB1:σ^A^~CTD~ complex molecules were found in each asymmetrical unit of the C222~1~ form and four copies in the P2~1~ form. Residues 2--73 of WhiB1 and residues 454--521 of σ^A^~CTD~ were included in the final model for the complexes of both crystal forms, while residues 2--75 of WhiB1 and 454--523 of σ^A^~CTD~ were included in at least one subunit of the refined model in the C222~1~ form. Notably, the structures of the WhiB1:σ^A^~CTD~ complex determined from the *C*222~1~ and P2~1~ forms agree closely, except for the flexible loop region containing residues Val20-Ala26 in WhiB1. The data collection and refinement statistics are summarized in Table [1](#tbl1){ref-type="table"}. Because of the better-defined electron density of residues at the N- and C-terminus, the refined structure in the C222~1~ form was used for generating the figures and analyzing the structure as described in the main text.

###### 

Data collection and refinement statistics

                                                                Crystal 1               Crystal 2               Crystal 1 data for phasing
  ------------------------------------------------------------- ----------------------- ----------------------- ----------------------------
  **Data collection** [**^a^**](#T1TFN1){ref-type="table-fn"}                                                   
  Space group                                                   *C*222~1~               *P*2~1~                 *C*222~1~
  Cell dimensions                                                                                               
   *a*, *b*, *c* (Å)                                            37.4, 114.1, 144.7      37.8, 144.4, 59.9       37.4, 114.1, 144.7
   α, β, γ (°)                                                  90.0, 90.0, 90.0        90.0, 106.8, 90.0       90.0, 90.0, 90.0
  Wavelength (Å)                                                0.9793                  0.9793                  0.9793
  Resolution (Å)                                                50--1.85 (1.88--1.85)   50--1.85 (1.87--1.85)   50--2.10 (2.16--2.10)
  *R* ~merge~                                                   0.095 (0.894)           0.061 (1.42)            0.073 (0.629)
  *I* / σ*I*                                                    36.8 (0.84)             22.3 (1.9)              24.3 (4.7)
  Completeness (%)                                              91.5 (56.4)             98.3 (98.3)             99.3 (93.7)
  Multiplicity\*                                                22.1 (13.2)             14.0 (14.4)             26.4 (26.8)
  CC~1/2~(%)                                                    99.8 (82.2)             99.9 (86.2)             99.3 (98.3)
  **Refinement**                                                                                                
  Resolution (Å)                                                50--1.85 (1.95--1.85)   50--1.85 (1.92--1.85)   
  No. reflections                                               20218                   51328                   
  No. molecules per asymmetric unit                             2                       4                       
  *R* ~work~/*R*~free~                                          0.189/0.236             0.193/0.234             
  No. atoms                                                     2531                    4821                    
  Protein                                                       2266                    4472                    
  Ligand                                                        30                      39                      
  Water                                                         235                     310                     
  *B*-factors                                                   34.94                   50.54                   
  Protein                                                       34.47                   50.64                   
  Ligand                                                        34.82                   42.34                   
  Water                                                         39.54                   50.12                   
  R.m.s deviations                                                                                              
   Bond lengths (Å)                                             0.007                   0.01                    
   Bond angles (°)                                              1.16                    1.21                    
  Ramachandran statistics                                                                                       
   Favored regions (%)                                          99.63                   98.87                   
   Allowed regions (%)                                          0.37                    1.13                    
   Outliers (%)                                                 0                       0                       
  PDB ID                                                        6ONO                    6ONU                    

^a^The highest-resolution shell statistics are shown in parentheses.

\*For the data used for phasing, the anomalous multiplicity was shown.

Structural figures were prepared with the PyMol Molecular Graphics System v 2.3 (<http://www.pymol.org>). Sequence and structural alignments were performed in Clustal Omega and ESpript online server (<http://espript.ibcp.fr>), respectively ([@B39],[@B40]). Tunnel dimensions were calculated using the Caver 3.0 software with probe radii indicated in the figures ([@B41]).

*In vitro* and *in vivo* protein-protein interaction assays {#SEC2-8}
-----------------------------------------------------------

The interactions between WhiB1 and His~6~-σ^A^~C170~ (wildtype and mutants) were carried out using two different approaches---*in vitro* pull-down assay and co-expression and affinity purification---to verify the effect of single mutations in either WhiB1 or σ^A^~C170~ on the WhiB1:σ^A^~C170~ complex formation.

For the *in vitro* pull-down assays, an equal amount of the purified His~6~-σ^A^~C170~ protein (wildtype or mutant) in 50 mM Tris--HCl, pH 8.0, 100 mM NaCl, 1 mM DTT was pre-loaded onto Ni^2+^-NTA Sepharose resin (GE Healthcare Life Sciences). An excess of tagless WhiB1 (either purified wildtype or the whole cell supernatant containing an over-expressed WhiB1 mutant) protein was then mixed with immobilized His~6~-σ^A^~C170~ on the Ni^2+^ Sepharose resin. After incubating for 5 minutes with gentle mixing followed by extensive washing with the same buffer containing 50 mM imidazole, His~6~-σ^A^~C170~ (alone or in complex with WhiB1) was eluted in the same buffer containing 250 mM imidazole and analyzed by SDS-PAGE. A negative control of the Ni^2+^ Sepharose resin without pre-incubated with His~6~-σ^A^~C170~ was used to exclude the possibility that tagless WhiB1 binds nonspecifically to the Ni^2+^ resin.

For the co-expression and affinity purification method, two plasmids containing genes encoding His~6~-σ^A^~C170~ and tagless WhiB1 (either wildtype or mutant), respectively, were co-transformed in *E. coli* BL21-Gold (DE3) strain. Protein co-expression and purification was performed similarly as described above, except that loose Ni^2+^ Sepharose HP resin was used for batch affinity purification of the His~6~-σ^A^~C170~-bound tagless WhiB1 (either the wildtype or mutants) simultaneously. For each sample, the whole cell supernatant from an equal amount of the cell pellet was mixed with Ni^2+^ Sepharose HP resin that had been pre-equilibrated in buffer containing 50 mM Tris--HCl, pH 8.0, 100 mM NaCl, 1 mM DTT. The resin was then washed with the same buffer containing 50 mM imidazole, followed by eluting the target proteins with the same buffer containing 250 mM imidazole. The eluted protein samples were analyzed by UV-Vis absorption spectroscopy and SDS-PAGE.

Electrophoretic mobility shift assay (EMSA) {#SEC2-9}
-------------------------------------------

The *whiB1* promoter (P*~whiB1~*) was amplified from the *M. tuberculosis* H37Rv genomic DNA (from 3595416 to 3595712 bp) and cloned into the EcoRI/HindIII site of the pUC18 vector. The resulting plasmid, pUC18-PwhiB1, was used as the template for preparing a biotin-labeled DNA probe using the 5′-biotin labeled M13F and M13R primers. The EMSA experiments were performed using the LightShift Chemiluminescent EMSA Kit (Thermo Fisher Scientific) as previously described ([@B6],[@B19]). The biotin-labeled probe (0.2 nM) was incubated with 0--12 μM of His~6~-σ^A^ or His~6~-σ^A^~C170~, either alone or pre-mixed with equimolar amounts of WhiB1, in 100 mM NaCl, 40 mM Tris--HCl, pH 8.0, 10 mM MgCl~2~, 1 mM EDTA, 0.25 mg/ml BSA and 1 mM DTT in a total volume of 20 μl. 50 ng/μl Poly (dI-dC) was included in all reactions as a non-specific competitor. After incubation on ice for 20 min, the reaction mix was subjected to electrophoretic separation in a 6% native polyacrylamide gel at 100 V in 0.5 × TBE buffer. DNA and DNA-protein complexes were transferred from the gel to a Hybond-N^+^ nylon membrane (GE Healthcare Life Sciences) and UV cross-linked to the membrane. The biotin-labeled DNA was detected using the LightShift Chemiluminescent EMSA Kit according to the manufacturer\'s instructions.

*In vitro* transcription assays {#SEC2-10}
-------------------------------

The *rrnAP3* DNA template used for *in vitro* transcription assays was amplified by PCR from the *M. tuberculosis* H37Rv genomic DNA (from 1471524 to 1471892 bp with an expected transcription product of 245 nt including 8 nt from the primer in the 3' end) and confirmed by DNA sequencing. For each 20-μl reaction, 250 nM RNAP holoenzyme was mixed with the desired amount of tagless WhiB1 (wildtype or F17A mutant) in the KCl assay buffer (10 mM Tris--HCl, pH 8.0, 50 mM KCl, 10 mM MgCl~2~, 0.1 mM EDTA, 0.1 mM DTT, 50 μg/ml BSA). A negative control reaction was performed simultaneously using 250 nM RNAP core enzyme without σ^A^ and WhiB1. The reaction mixtures were incubated for 10 min at room temperature under anaerobic conditions. The *rrnAP3* DNA template was then added to each reaction mixture at a final concentration of 50 nM and incubated at room temperature for an additional 10 min. Transcription was initiated by adding NTP mix (ATP, CTP and GTP at a final concentration of 100 μM) and 1.0 μCi of \[α-^32^P\]UTP (800 Ci mmol^−1^, PerkinElmer Life Sciences). After incubation at 37°C for 5 min, the reaction was stopped with a 2X Stop buffer (45 mM Tris--HCl, 45 mM boric acid, 8 M urea, 30 mM EDTA, 0.02% bromophenol blue, 0.02% xylene cyanol). Transcription products were denatured by heating at 95°C, separated on polyacrylamide gels, and visualized using a phosphorimager.

RESULTS {#SEC3}
=======

Crystallization and structural determination of the *M. tuberculosis* WhiB1:σ^A^~CTD~ complex {#SEC3-1}
---------------------------------------------------------------------------------------------

To improve protein stability and enable crystallization of the WhiB1:σ^A^~CTD~ complex, we made a truncated WhiB1 (aa 1--76) construct that lacks the unstructured C-terminal loop, and a σ^A^ construct that contains only the last 112 residues (aa 417--528). The constructs were designed based on the previously reported NMR structure of free WhiB1 and the cryo-EM structure of σ^A^ in the *M. tuberculosis* RNAP holoenzyme ([@B8],[@B32]). The resulting WhiB1 (without a tag) and σ^A^ (with a His~6~ tag) constructs were then co-expressed and purified from *E. coli*, and crystallized under anaerobic conditions (see MATERIALS AND METHODS).

Experimental phases were determined by single-wavelength anomalous dispersion (SAD) from the SeMet-substituted WhiB1:σ^A^~C112~ complex, and the structure was solved and refined at 1.85 Å resolution using Phenix and COOT (see MATERIALS AND METHODS, [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}) ([@B37],[@B38]). The data processing and refinement statistics are summarized in Table [1](#tbl1){ref-type="table"}.

Overall structure of the WhiB1:σ^A^~CTD~ complex {#SEC3-2}
------------------------------------------------

The structure of the WhiB1:σ^A^~CTD~ complex shows that WhiB1 and σ^A^~CTD~ interact with each other at the \[4Fe--4S\] cluster binding pocket of WhiB1 (Figure [1](#F1){ref-type="fig"}). An all-helical fold is adopted by both WhiB1 and σ^A^~CTD~, with helices h~w~1--4 of WhiB1 and h~s~1--4 of σ^A^~CTD~, respectively (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). The complex is hinged at the \[4Fe--4S\] cluster and forms a clamp between the C-terminal helices of WhiB1 (h~w~4) and σ^A^~CTD~ (h~s~4) (Figure [1B](#F1){ref-type="fig"}), both of which have been implicated in DNA binding ([@B19],[@B32],[@B42],[@B43]).

![Overview of the WhiB1:σ^A^~CTD~ complex from *M. tuberculosis*. (**A**) Domain organization of σ^A^ and WhiB1 in *M. tuberculosis* based on the primary and 3D structural analysis. The conserved domains are shown in rectangles, while the variable regions are represented by thin sticks. The regions included in the refined crystal structure are indicated by the dash lines. (**B** and **C**) Cartoon and surface representation, respectively, of the WhiB1:σ^A^~CTD~ complex. The \[4Fe--4S\] cluster of WhiB1 is shown in ball-and-stick representation, with Fe atoms colored orange and yellow for S. The clamp shape formed between the C-terminal helices of WhiB1 (h~w~4) and σ^A^~CTD~ (h~s~4) is highlighted by the arrow. (**D**) Crystal structure of WhiB1 in the complex is superimposed with the NMR structure of free WhiB1 (PDB ID: 5OAY, in pink). Only the first model of the NMR structure is shown for clarity. (**E**) Crystal structure of σ^A^~CTD~ in the complex is superimposed to the cryo-EM structure of *M. tuberculosis* RNA polymerase -- DNA complex (PDB ID:6C04, in pink). The region different between the two structures at the C-terminus of σ^A^~CTD~ is highlighted in the circle.](gkz1133fig1){#F1}

Structural comparison demonstrates that both WhiB1 and σ^A^~CTD~ undergo conformational changes upon forming the complex. An overlay of the WhiB1:σ^A^~CTD~ complex with the NMR structure of free WhiB1 reveals a global structural rearrangement upon σ^A^~CTD~ binding ([@B8]). This includes changes in the inter-helical and helix-loop interactions, and the breaking of helix h~w~1 into two shorter helical regions (h~w~1a and b) (Figure [1D](#F1){ref-type="fig"}). Helix h~w~4 and the following C-terminal DNA binding motif move concomitantly with the structural rearrangement. In the NMR structure of free WhiB1, helix h~w~4 is interlocked with h~w~2, which has been cited to explain why free holo-WhiB1 does not bind to DNA ([@B8]). In the WhiB1:σ^A^~CTD~ complex helix h~w~4 of WhiB1 is about 120° apart from its corresponding position in free WhiB1 and is released from h~w~2 (Figure [1D](#F1){ref-type="fig"}). The conformation of h~w~4 in the complex appears stabilized by the interaction with h~w~3. The h~w~4 conformation may also be stabilized in part by crystal contacts between WhiB1 and σ^A^~CTD~**′** in the second complex molecule of the asymmetric unit ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), while it is expectedly more flexible in solution. The overall conformation of σ^A^~CTD~ in the complex is similar to that in the *Mtb* RNAP holoenzyme, except for the C-terminus of helix h~s~4 (Figure [1E](#F1){ref-type="fig"}).

The molecular interface of WhiB1 and σ^A^~CTD~ {#SEC3-3}
----------------------------------------------

Our structural analysis indicates that the interaction between WhiB1 and σ^A^~CTD~ involves considerable hydrophobic contacts around the \[4Fe--4S\] cluster binding pocket. As shown in Figure [2](#F2){ref-type="fig"}, His516 and Pro517 in the C-terminal loop of σ^A^~CTD~ insert into the \[4Fe--4S\] cluster binding pocket of WhiB1. There is a cluster of hydrophobic residues around the Fe--S cluster binding pocket, including Trp3, Phe17, Trp60 and Phe18 (Figure [2](#F2){ref-type="fig"}, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Each of these aromatic residues is highly conserved in WhiB1 across different classes of the phylum Actinobacteria ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

![Molecular interface of WhiB1 and σ^A^~CTD~. (**A**) Open-book view of Figure [1C](#F1){ref-type="fig"}. Residues in contact at the interface of WhiB1 and σ^A^~CTD~ are labeled, with the hydrophobic residues colored brown and the charged residues at the surface colored wheat, respectively. (**B**) Close-up view of the insertion of His516 and Pro517 of σ^A^~CTD~ into the \[4Fe--4S\] cluster binding pocket of WhiB1, surrounded by four aromatic residues (Trp3, Phe17, Phe18 and Trp60) shown in sticks. The polar interactions of the His516 imidazole ring with Val59 and the \[4Fe--4S\] cluster, respectively, in WhiB1 are highlighted by red dash lines. The \[4Fe--4S\] cluster of WhiB1 is shown in ball-and-stick representation, with the carbon atoms of WhiB1 and in σ^A^~CTD~ colored palegreen and grey, respectively; Fe in orange; N in blue; O in red; and S in yellow. (**C**) and (**D**) are the SDS-PAGE analyses of the samples from *in vitro* pull-down assays. In Panel **C**, the purified His~6~-σ^A^~C170~ proteins (either wildtype or mutants as indicated) were used as the bait, and the purified tagless wildtype WhiB1 protein was used as the prey. In Panel **D**, the purified wildtype His~6~-σ^A^~C170~ protein was used as the bait, and the whole cell supernatant containing a tagless WhiB1 mutant was used as the prey. The purified tagless WhiB1 and His~6~-σ^A^~C170~ were loaded in the first two lanes in Panel C as reference. In the negative control (NC), only tagless WhiB1 was used in the pull-down assay without the presence of the bait (His~6~-σ^A^~C170~).](gkz1133fig2){#F2}

To test the importance of these hydrophobic residues for the interaction of WhiB1 with σ^A^~CTD~, His516 and Pro517 were substituted with Ala in σ^A^~C170~ (containing the last 170 residues 359--528 of σ^A^ and the intact σ^A^~4~). Protein-protein interaction assays with σ^A^~C170~ H516A and P517A mutants indicate that these hydrophobic residues are critical for WhiB1 binding. Substitution of either His516 or Pro517 by Ala completely abolishes the interaction between WhiB1 and σ^A^~C170~ as observed both *in vitro* pull-down assay and in co-expression and affinity purification, establishing the functional importance of these residues (Figure [2C](#F2){ref-type="fig"}, [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Likewise, an F17A or F18A substitution in WhiB1 abolishes the interaction between WhiB1 and σ^A^~C170~, while neither shows a significant effect on \[4Fe--4S\] cluster binding in WhiB1 (Figure [2D](#F2){ref-type="fig"}, Supplementary Figures. S5 and S6). Substitution of the Trp residues in WhiB1 shows varied effects on complex formation as well as the stability of the \[4Fe--4S\] cluster, which is discussed in detail in the following section.

Besides the aforementioned hydrophobic interactions, a His516-centered hydrophilic network is also required for the interaction between WhiB1 and σ^A^~CTD~. As highlighted in Figure [2B](#F2){ref-type="fig"}, Nϵ2 of His516 forms a 2.8-Å hydrogen bond with the carbonyl O of Val59. In addition, Nϵ2 of His516 is 3.5 Å away from a bridging sulfide (S4) in the \[4Fe--4S\] cluster and thus it may form a polar interaction with the cluster. To evaluate the importance of the His516-centered hydrophilic network for the complex formation, we substituted His516 with Phe in σ^A^~C170~. The σ^A^~C170~ H516F mutant completely abolishes binding to WhiB1 (Figure [2C](#F2){ref-type="fig"}, [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). When replacing His516 with Phe in the crystal structure, the shortest distance between the modeled Phe and any non-bonded residues is ∼2.4 Å, suggesting that the observed effect of the H516F mutation is more likely due to disruption of the His516-centered polar interactions rather than due to a steric effect considering the flexibility of the loops in this region.

To test whether disruption of the WhiB1:σ^A^~4~ interaction affects WhiB1's essential role in mycobacteria, residues Phe17 and Phe18 in *whiB1*, both of which are required for σ^A^~4~ binding *in vitro*, were mutated to Ala and the impacts on the cell growth in the non-pathogenic mycobacterial model *Mycobacterium smegmatis* (*M. smegmatis*) were assessed. All *M. tuberculosis* Wbl proteins except WhiB5 are highly conserved in *M. smegmatis*. In particular, the WhiB1 proteins from *M. Smegmatis* and *M. tuberculosis* share 96% sequence identity, with variations in only three residues ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Moreover, as demonstrated in *M. tuberculosis* ([@B6]), deletion of *whiB1* is lethal in *M. smegmatis* unless a complementary copy of *whiB1* is present (see MATERIALS and METHODS, [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). These results establish that *M. smegmatis* is a suitable mycobacterial model for the functional studies of WhiB1. We found that substitution of either Phe17 or Phe18 with Ala in *whiB1* is lethal in *M. smegmatis*, consistent with their essential role in the WhiB1:σ^A^~C170~ interaction *in vitro*. These results indicate that the interaction between WhiB1 and σ^A^~4~ is required for WhiB1's essential role in mycobacterial growth.

Surface charge complementarity is a common mechanism used by σ^70^~4~-bound transcription activators ([@B7],[@B11],[@B12]) but it does not seem to be a critical mechanism for stabilizing the WhiB1:σ^A^~CTD~ complex. As shown in Figure [2A](#F2){ref-type="fig"}, there are two regions in the complex interface that contain oppositely charged residues (Arg4 and Arg10 in WhiB1 versus Ser518 and Ser520 in σ^A^~CTD~; Glu15 and Gln55 in WhiB1 versus Lys513 and Arg515 in σ^A^~CTD~). However, the residue contacts in these two regions vary significantly between two copies of the complex molecules in the asymmetric unit of the crystal structure ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}), suggesting that they do not drive complex formation. As expected, a single mutation of the selected residues (Glu15 in WhiB1; Lys513, Arg515, Ser518 and Ser520 in σ^A^~CTD~) in these two regions did not show significant effects on the WhiB1:σ^A^~C170~ complex formation (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}, [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Arg515 lies close to the WhiB1:σ^A^~CTD~ interface. While this residue is required for σ^A^ binding and transcription activation by several *M. tuberculosis* Wbl proteins, it is not required by WhiB1 ([@B7],[@B11],[@B12]). In the crystal structure of WhiB1:σ^A^~CTD,~ the sidechain of Arg515 protrudes out towards the solvent and does not make close contacts with any residues in WhiB1, explaining why Arg515 in WhiB1 is not required for σ^A^ binding.

Taken together, our structural analyses and protein-protein interaction assays demonstrate that the formation of the WhiB1:σ^A^~CTD~ complex is driven by a combination of hydrophobic contacts and His516-centered polar interactions inside the Fe--S cluster binding pocket, instead of surface charge complementarity. The site-directed mutagenesis studies on *whiB1* in *M. smegmatis* support that the interaction with σ^A^ is required for the essential role of WhiB1, revealing a potential mechanism of action for holo-WhiB1 in supporting mycobacterial growth.

The local environment of the \[4Fe--4S\] cluster binding pocket in the WhiB1:σ^A^~CTD~ complex {#SEC3-4}
----------------------------------------------------------------------------------------------

The WhiB1:σ^A^ complex has been reported to be O~2~--stable ([@B8]). This differs from other structurally-characterized gas molecule sensors containing a \[4Fe--4S\] cluster, for example the O~2~/NO sensor FNR and the NO sensor NsrR, both of which are highly sensitive to O~2~ ([@B44]). Examination of the local environment surrounding the \[4Fe--4S\] cluster in the WhiB1: σ^A^~CTD~ complex reveals the structural basis for its exceptional O~2~ stability. As shown in Figure [3A](#F3){ref-type="fig"}, the protein environment surrounding the \[4Fe--4S\] cluster binding site is altered in the WhiB1:σ^A^~CTD~ complex relative to free WhiB1. The most noticeable differences include four aromatic residues (Trp3, Phe17, Phe18 and Trp60) that are closer to the Fe--S cluster binding pocket, while the side chain of Trp49 faces away from the cluster in the WhiB1:σ^A^~CTD~ complex relative to free WhiB1.

![Structural basis for the stability of the \[4Fe--4S\] cluster in the WhiB1:σ^A^~CTD~ complex. (**A**) Comparison of the crystal structure of the σ^A^~CTD~--bound WhiB1 with the NMR structure of free WhiB1 (PDB ID: 5OAY) aligned at the Fe-S cluster binding site. Only the first model of the NMR structure is shown for clarity. The \[4Fe--4S\] cluster and the aromatic residues near the cluster for the σ^A^~CTD~--bound WhiB1 are shown in the ball-and-stick and stick representation, respectively; while their corresponding residues in free WhiB1 are shown in thin lines. The carbon atoms are colored pale green for the σ^A^~CTD~--bound WhiB1 and grey for free WhiB1. Other non-carbon atoms in this figure are colored by the element type: blue for N, red for O, orange for Fe and orange and yellow for S. (**B**) Stick representation of the local environment of the \[4Fe--4S\] cluster binding pocket. The \[4Fe--4S\] cluster is shown in ball-and-stick representation. The carbon atoms are colored pale green for WhiB1 and grey for σ^A^~CTD~. (**C**) Solvent-accessible paths from the surface towards the \[4Fe--4S\] cluster in FNR (PDB ID: 5E44) and NsrR (PDB ID:5N07) were calculated by CAVER with a shell radius of 1.4 Å, which is the assumed radius cutoff for solvent molecules. The paths are highlighted in pink and the minimum bottleneck of each path is indicated. No solvent-accessible path is found in the WhiB1:σ^A^~CTD~ complex with a shell radius of 1.4 Å. Instead the largest tunnel found in the WhiB1:σ^A^~CTD~ complex with the minimum bottleneck of 0.8 Å is shown for demonstration and is highlighted in cyan.](gkz1133fig3){#F3}

As a result of the conformational changes upon σ^A^~4~ binding, the \[4Fe--4S\] cluster of the complex is enclosed in a hydrophobic core consisting of several short-chain hydrophobic residues besides the three aromatic residues of WhiB1 (Trp3, Phe17 and Trp60) and His516 and Pro517 of σ^A^~CTD~ mentioned above (Figure [3B](#F3){ref-type="fig"}). The side chains of the polar residues (Arg4, Arg10 and Thr43 in WhiB1 and Ser518 in σ^A^~CTD~) around the \[4Fe--4S\] cluster all protrude from the cluster, with the sole exception of His516 in σ^A^~CTD~. Apart from the imidazole ring of His516, six backbone amides are found within 4 Å of the sulfur ligands of the \[4Fe--4S\] cluster in the complex. The dipoles of these peptide backbone amides may stabilize the cluster via a protein-derived electrostatic field ([@B48],[@B49]). Cavity analysis indicates that the biggest channel extending from the WhiB1:σ^A^~CTD~ surface to the \[4Fe--4S\] cluster has a minimum bottleneck of ∼0.8 Å. Assuming a 1.4-Å radius cutoff for water molecules, this indicates that the solvent accessibility to the \[4Fe--4S\] cluster in the complex is highly limited (Figure [3C](#F3){ref-type="fig"}). In contrast, multiple channels with a minimum bottleneck of ∼1.4 Å or larger to the \[4Fe--4S\] cluster in either FNR or NsrR homodimer structures have been identified by cavity analysis, suggesting that the Fe-S clusters of these two proteins remain fully accessible to solvent. Our cavity analysis indicates that solvent accessibility is correlated with the O~2~ stability of the \[4Fe--4S\] clusters in these proteins.

The characteristics of the local environment around the \[4Fe--4S\] cluster in the WhiB1:σ^A^~CTD~ complex resemble that of the high potential iron-sulfur proteins (HiPIPs) involved in electron transport ([@B50],[@B51]). As indicated by the name, HiPIPs have an unusually high redox potential compared to many other \[4Fe--4S\] ferredoxins, and undergo a 3+/2+ rather than 2+/1+ redox cycle under physiological conditions ([@B48]). HiPIPs are O~2~-stable owing to their high redox potentials, but remain reactive to NO ([@B52],[@B53]). The presence of a hydrophobic barrier composed of aromatic residues, solvent inaccessibility of the \[4Fe--4S\] cluster, and electrostatic interactions with local backbone amides have been suggested to play a major role in improving the O~2~ stability of HiPIPs ([@B48],[@B49],[@B51],[@B54]). We predict that similar features of the local environment surrounding the \[4Fe--4S\] cluster in the WhiB1:σ^A^~CTD~ complex may increase its redox potential as in HiPIPs and thus improve the cluster stability in the presence of O~2~.

To identify the critical residues near the Fe--S cluster and to test whether aromatic residues and/or solvent accessibility contribute to the stability of the \[4Fe--4S\] cluster in the WhiB1:σ^A^~CTD~ complex as demonstrated in HiPIPs, we carried out an alanine scanning mutagenesis of the three Trp residues near the cluster in WhiB1. The first Trp residue we examined is Trp3. As shown in Figure [3A](#F3){ref-type="fig"}, Trp3 is close to the \[4Fe--4S\] cluster of the complex and stands at the protein surface facing bulk solvent in this crystal structure. Cavity analysis predicts that a W3A mutation would open a pore in the cluster binding pocket large enough for solvent access to the cluster in the complex (Figure [4A](#F4){ref-type="fig"}). However, Trp3 is far from the Fe--S cluster (\>7.5 Å in all models) in the NMR structure of free WhiB1, and no conformational change of Trp3 was detected upon σ^A^ binding by the NMR chemical shift perturbation analysis ([@B8]). To evaluate the effect of Trp3 on the Fe-S cluster stability in free WhiB1 and in the WhiB1:σ^A^~CTD~ complex, we characterized the WhiB1 W3A mutant *in vitro* and in *M. smegmatis*. As shown in [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}, we found that the W3A mutation in WhiB1 results in a severe loss of the \[4Fe--4S\] cluster and diminishes the stability of WhiB1 when expressed and purified alone. The W3A mutation also disrupts WhiB1's interaction with σ^A^~C170~, most likely due to the instability of the cluster ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}, [Supplementary Figure S6B](#sup1){ref-type="supplementary-material"}). In *M. smegmatis*, the *whiB1-W3A* mutant showed a significant defect in cell growth under optimal growth conditions (Figure [4B](#F4){ref-type="fig"}). These observations unambiguously indicate, that Trp3 is crucial for the stability of the Fe--S cluster in WhiB1 and the interaction between WhiB1 and σ^A^, consistent with our crystal structural analysis but different from the reported NMR studies ([@B8]). These results also corroborate that binding to σ^A^ is required for WhiB1's role in mycobacterial growth as described above in the mutagenesis studies on Phe17 and Phe18 in WhiB1.

![Effect of Trp3 on the stability of the \[4Fe--4S\] cluster in the WhiB1:σ^A^~CTD~ complex. (**A**) Solvent-accessible path from the surface towards the \[4Fe--4S\] cluster in the mutated model of the WhiB1-W3A:σ^A^~CTD~ complex was calculated by CAVER 3.0 with a shell radius of 1.4 Å. The minimum bottleneck of the path is 1.7 Å. (**B**) Cell growth of *M. smegmatis* wildtype (WT) and the *whiB1-W3A* mutant on either a 7H10 agar plate for 3 days (top) or in 7H9 broth under optimal growth conditions. Error bars in the growth curves represent the standard deviation of triplicate samples.](gkz1133fig4){#F4}

In contrast to Trp3, the WhiB1-W49A mutant protein has properties comparable to those of the wildtype WhiB1 in SDS-PAGE and UV-Visible spectral analyses when co-expressed and purified as a complex with His~6~-σ^A^~C170~ from *E. coli* ([Supplementary Figures S5C and S6B](#sup1){ref-type="supplementary-material"}). However, when expressed and purified alone from *E. coli*, WhiB1-W49A exhibits a less stable \[4Fe--4S\] cluster based on the UV-Visible spectra and has weaker binding to σ^A^~C170~ in the *in vitro* pull-down assay (Figure [2D](#F2){ref-type="fig"}, [Supplementary Figures S5 and S6](#sup1){ref-type="supplementary-material"}). These results indicate that Trp49 in WhiB1 undergoes a conformational change upon σ^A^~CTD~ binding as suggested by the structural comparison between the NMR structure of free WhiB1 and our crystal structure of the WhiB1:σ^A^~CTD~ complex (Figure [3A](#F3){ref-type="fig"}). The mutation of Trp60 (W60A), on the other hand, has little effect either on the stability of the \[4Fe--4S\] cluster or on its binding to σ^A^~C170~ (Figure [2D](#F2){ref-type="fig"}, Supplementary Figures. S5 and S6). This is likely because Trp60 is buried inside the Fe--S cluster binding pocket in the complex and is not exposed to the bulk solvent.

Altogether, our structural and biochemical analysis indicate that the unusually hydrophobic, solvent-inaccessible local environment surrounding the \[4Fe--4S\] cluster in the WhiB1:σ^A^~CTD~ complex makes the cluster remarkably stable to O~2~ and thus favorable for NO sensing in aerobic environments.

WhiB1 represses transcription by interacting with σ^A^~4~ in the RNAP holoenzyme {#SEC3-5}
--------------------------------------------------------------------------------

When superimposing σ^A^~CTD~ in the WhiB1:σ^A^~CTD~ complex on the cryo-EM structure of the *M. tuberculosis* RNAP--DNA complex, we find no steric clash between WhiB1 and the core subunits in the RNAP holoenzyme (Figure [5A](#F5){ref-type="fig"}) ([@B32]). We thus predict that WhiB1 can bind to σ^A^~4~ in the RNAP holoenzyme. To test this, we first incubated either the RNAP holoenzyme or core enzyme with and without σ^A^, respectively, in the presence of an excess amount of the 3FLAG-tagged holo-WhiB1 under anaerobic conditions. The mixtures were then separated by size exclusion chromatography, and the peak fractions were collected for SDS-PAGE and western blot analysis. The results clearly demonstrate that WhiB1 forms a stable complex with the RNAP holoenzyme in a σ^A^--dependent manner (Figure [5B](#F5){ref-type="fig"}).

![WhiB1 represses transcription from the *rrnAP3* promoter *in vitro* by interaction with σ^A^ in the RNA polymerase holoenzyme. (**A**) Superimposition of the WhiB1-bound σ^A^~CTD~ and σ^A^~CTD~ onto the *M. tuberculosis* RNAP--DNA complex (PDB ID: 6C04). The residues implicated in DNA binding in WhiB1 and σ^A^~4~ are highlighted. (**B**) Detection of complex formation between WhiB1 and σ^A^ in RNAP by size-exclusion chromatography. 3FLAG-WhiB1 was detected by SDS PAGE (as indicated by the arrow) and western blot analysis using anti-FLAG M2 antibody (Sigma) in the peak fraction of the sample containing the RNAP holoenzyme preincubated with 3FLAG-WhiB1, but not in the sample either containing the RNAP holoenzyme alone or containing the RNAP core enzyme (without σ^A^) either or not preincubated with 3FLAG-WhiB1. (**C**) Cell growth curves of *M. smegmatis* wildtype (WT) and the *whiB1* truncation mutant (WhiB1-ATD) without the C-terminal DNA binding motif, AT-hook, in 7H9 broth under optimal growth conditions. (**D**) *In vitro* transcription from the *rrnAP3* promoter in the absence and presence of the wildtype WhiB1 or the WhiB1-F17A mutant. Each 20-μl reaction contains the RNAP holoenzyme (250 nM), the *rrnAP3* DNA template (10 nM), and varying amounts of the wild-type WhiB1 or WhiB1-F17A mutant as indicated. The reaction buffer contains 10 mM Tris-HCl, pH 8.0, 50 mM KCl, 10 mM MgCl~2~, 0.1 mM EDTA, 0.1 mM DTT, and 50 μg/ml BSA. The RNAP holoenzyme was pre-incubated with the WhiB1 proteins under anaerobic conditions before adding the *rrnAP3* DNA template. The RNAP core enzyme (250 nM) was used as a negative control (NC). The *in vitro* transcript products were separated on 8M-6% polyacrylamide gels, and the full gel images are shown in [Supplementary Figure S8](#sup1){ref-type="supplementary-material"}.](gkz1133fig5){#F5}

The superimposed structure also reveals that the clamp comprising the C-terminal helix h~w~4 in WhiB1 and helix h~s~4 in σ^A^~CTD,~ is positioned across the DNA helix of the -35 element in the RNAP--DNA complex (Figure [5A](#F5){ref-type="fig"}). Several residues of σ^A^~CTD~ implicated in DNA binding align along the inner interface of the clamp and are in close contact with DNA (the inset of Figure [5A](#F5){ref-type="fig"}) ([@B32]). Helix h~w~4 of WhiB1 and the DNA binding motif immediately following the C-terminus of this region straddle the DNA helix (the inset of Figure [5A](#F5){ref-type="fig"}). However, none of the residues in the C-terminal DNA binding motif of WhiB1 seem to be close enough for DNA binding in this superimposed model. Considering the flexibility of the loop structure on both ends of WhiB1 h~w~4, we could not rule out the possibility that σ^A^--bound WhiB1 is potentially involved in DNA binding in solution. To address this possibility, we examined the effect of WhiB1 on σ^A^ binding to the *whiB1* promoter (P*~whiB1~*) by electrophoretic mobility shift assays (EMSAs). The results from EMSA assays indicate that addition of WhiB1 to either σ^A^~C170~ or σ^A^ does not enhance its binding to P*~whiB1~* under the experimental conditions ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}).

To test whether the C-terminal DNA binding motif (AT-hook) of WhiB1 is required for its essential role in mycobacterial growth, we constructed a truncation mutant of *whiB1* in *M. smegmatis* with a deletion of the AT-hook (*whiB1-ATD*). In this mutant, the last 13 residues (Lys72--Val84), including five Lys and Arg residues that are required for DNA binding by apo-WhiB1 ([@B19]), are removed from the *whiB1* gene by homologous recombination-based in-frame unmarked deletion (see MATERIALS AND METHODS, [Supplementary Figure S1D](#sup1){ref-type="supplementary-material"}). As shown in Figure [5C](#F5){ref-type="fig"}, we find that the growth rate of the *whiB1-ATD* mutant was comparable to the wildtype strain under optimal growth conditions, indicating that the single DNA binding motif of WhiB1 is dispensable to *M. smegmatis* viability under non-stressed conditions.

The results from our structural analysis and the mutagenesis study on the single DNA binding motif in WhiB1 described above led us to search for an alternative mechanism of transcriptional regulation by holo-WhiB1 different from that of a canonical σ^A^~4~-dependent transcription activator. A close examination of the overlaid structures between the WhiB1:σ^A^~CTD~ complex and *M. tuberculosis* RNAP indicates that the WhiB1 binding site on σ^A^~4~ overlaps with the C-terminal domain of the α subunit (α~CTD~) in RNAP. α~CTD~ is separated from the N-terminal domain of the α subunit by a long flexible linker that is absent in most mycobacterial RNAP structures ([@B55]). In *E. coli* and *Bacillus subtilis*, α~CTD~ binds to the A/T-rich regions upstream of the −35 element (UP element) for transcription factor--independent activation of many promoters, including the gene encoding 16S rRNA ([@B56],[@B57]). A similar mechanism of transcriptional regulation by α~CTD~ likely exists in *M. tuberculosis* based on the 3D structure of RNAP and sequence analysis of potential UP elements in promoters ([@B55]). If so, WhiB1 binding to σ^A^~CTD~ may block the access of α~CTD~ to the UP element and thus interfere with the α~CTD~-dependent transcription.

To test this hypothesis, we examined the effect of WhiB1 on the *in vitro* transcription of the *M. tuberculosis rrs* gene encoding 16S rRNA from the *rrnAP3* promoter in *M. tuberculosis* ([@B58]). The results shown in Figure [5D](#F5){ref-type="fig"} indicate a clear concentration--dependent transcription repression from *rrnAP3* by the wildtype WhiB1 but not the WhiB1-F17A mutant, which does not bind to σ^A^~4~. Thus, we conclude that the transcription repression from *rrnAP3* by holo-WhiB1 requires its interaction with σ^A^~4~ under these experimental conditions. To evaluate the effect of WhiB1 on the promoter escape, we examined the abortive transcripts from the *in vitro* transcription reaction mixtures. As shown in [Supplementary Figure S9](#sup1){ref-type="supplementary-material"}, we find that addition of WhiB1 does not cause an increase in abortive transcripts, which would be expected if WhiB1 repressed gene expression by inhibiting promoter escape. This observation is consistent with our hypothesis that WhiB1 represses transcription from *rrnAP3* by preventing α~CTD~ from binding to the UP element.

DISCUSSION {#SEC4}
==========

In the present report, we provide the first atomic view of the molecular interface between WhiB1 and σ^A^~CTD~ and establish the structural basis for the O~2~ stability of the \[4Fe--4S\] cluster in the σ^A^~CTD~--bound WhiB1. We also demonstrate that WhiB1 can repress gene expression by interaction with σ^A^ in the RNAP holoenzyme *in vitro*, and that the interaction between WhiB1 and σ^A^~4~ is essential for supporting mycobacterial growth *in vivo*. As discussed below, these data suggest that WhiB1 regulates gene expression by a non-canonical mechanism that is distinguished from to the promoter-centered, Class II transcription activation typically observed with σ^70^~4~--bound transcription activators (Figure [6](#F6){ref-type="fig"}) ([@B10],[@B23]).

![Proposed working model of holo-WhiB1 in transcriptional regulation via interaction with σ^A^~4~. (**A**) Diagram that demonstrates the α~CTD~-mediated transcription factor--independent activation by recognizing the up element (UP) of the target promoters. (**B** and **C**) Diagrams of the Class I and Class II transcription activation, respectively. The 3D structures of the cyclic AMP receptor protein (CRP) bound RNAP--DNA complexes for the CRP-dependent Class I and Class II transcription activation (PDB IDs: 3IYD and 5I2D, respectively) are used as models. (**D** and **E**) Diagrams of the proposed working model for holo-WhiB1 in transcriptional regulation via interaction with σ^A^~4~. Panel **D** illustrates that WhiB1 binding to σ^A^~4~ can block the binding site for activators or α~CTD,~ and thus repress transcription. Panel **E** shows that WhiB1 binding to σ^A^~4~ in RNAP, either alone or in concert with a to-be-defined transcription regulator, may stabilize the interaction between RNAP and a specific subset of promoters, and thus activate transcription.](gkz1133fig6){#F6}

The crystal structure of the WhiB1:σ^A^~CTD~ complex reported here not only provides long-sought atomic detail about the interaction between σ^A^~4~ and a Wbl protein, but also reveals how a monomeric transcription regulator with a single DNA binding motif interacts with σ^A^~4~ in bacteria. A genome-wide survey of oligomerization states of transcription factors from *M. tuberculosis* suggests that monomeric transcription factors are more abundant than the few that have been characterized ([@B7]). For example, two essential monomeric transcription factors, RbpA and CarD, have recently been identified as global transcription regulators. They stabilize the RNAP--DNA open complex in *M. tuberculosis* via interaction with RNAP (including regions 2 and 3 of σ^A^) and the fork-junction promoter DNA near the -10 element with low sequence specificity ([@B59]). Considering the structure of WhiB1, we expect that holo-WhiB1 may have low DNA specificity like RbpA and CarD, if it binds to DNA at all. This speculation is supported by our observation that WhiB1 does not significantly enhance the binding affinity of σ^A^ to the *whiB1* promoter in the EMSA assays, and that the single DNA binding motif of WhiB1 is not required for its essential role in supporting mycobacterial growth. Although we cannot rule out the possibility that σ^A^~4~--bound WhiB1 may recognize target gene promoters other than *whiB1* itself, such a case has not yet been reported for a canonical Class II transcription activator in bacteria. As a σ^A^~4~-bound transcription regulator, WhiB1 is more likely to be involved in differentiation of gene expression by modulating the DNA binding preference of RNAP, rather than facilitating the transition and stabilizing the open state of the RNAP--DNA complex as RbpA and CarD do.

A key finding in this report is the unusual hydrophobic residue-driven interaction between WhiB1 and σ^A^~4~, which induces conformational changes in both binding partners. This distinguishes WhiB1 from other well-characterized Class II transcription activators (i.e. CRP and FNR) that bind directly to σ^70^~4~ ([@B10],[@B23]). In the canonical Class II activation mechanism, transcription activators recognize and bind to the target DNA sequence adjacent to the -35 element, and then recruit RNAP to the site for the initiation of transcription via contact with σ^70^~4~ (Figure [6](#F6){ref-type="fig"}). Although less common, there are examples of transcription activators, such as SoxS involved in redox stress response, that can bind to σ^70^~4~ in RNAP without the presence of target DNA via the pre-recruitment mechanism ([@B27]). In either case, these transcription activators are in loose contact with σ^70^~4~ through surface charge complementarity, and typically do not induce conformational changes in either protein ([@B11],[@B12],[@B21]). The loose interaction with σ^70^~4~ is consistent with the promoter-centered activation mechanism, which requires rapid disassociation between the transcription activator and RNAP upon initiation of transcription, and release of RNAP for recruitment by other σ^70^~4~--dependent transcription factors. The hydrophobic residue-driven interaction between WhiB1 and σ^A^~4,~ on the other hand, is incompatible with such a mechanism. Interestingly, a similar interaction with σ^70^~4~ has been observed with the so-called "phage appropriator" AsiA, a viral transcription regulator from the bacteriophage T4 that remodels the DNA preference of host RNAP by a mechanism of σ appropriation ([@B62],[@B63]). In this mechanism, AsiA binds tightly to σ^70^~4~ in *E. coli* RNAP and induces conformational changes in σ^70^~4~ so that it cannot recognize the --35 element of host genes; instead the phage activator MotA makes use of the remodeled σ^70^~4~ in host RNAP to express genes in the middle stage of the phage T4 life cycle.

Besides the σ^A^~4~--bound transcription activators, the interaction interface of WhiB1 and σ^A^ also overlaps with α~CTD~ in RNAP. In bacteria, α~CTD~ not only binds to the UP elements for transcription factor--independent activation of many promoters, but also plays a major role in transcriptional regulation through interaction with Class I and Class II transcription factors (Figure [6A](#F6){ref-type="fig"}-[C](#F6){ref-type="fig"}) ([@B64]). The effect of WhiB1 on *in vitro* transcription that we observe aligns with previous studies on the 3D structure of RNAP and sequence analysis of potential UP elements in promoters in *M. tuberculosis* ([@B55]), suggesting that α~CTD~ may play a similar role in transcriptional regulation in mycobacteria as reported in *E. coli* and other bacteria. How the interaction between WhiB1 and σ^A^ influences the functional role of α~CTD~ and σ^A^~4~--bound transcription activators warrants further investigation.

Considering all the evidence together, we propose that holo-WhiB1 regulates gene expression by modulating the promoter recognition preference of RNAP during transcription initiation (Figure [6D](#F6){ref-type="fig"} and [E](#F6){ref-type="fig"}). This working model accounts for our observation of an unusual hydrophobic residue-driven interaction between holo-WhiB1 and σ^A^~4~ and high levels of expression of WhiB1 relative to σ^A^ in *M. tuberculosis*, as reported previously ([@B5]). On one hand, owing to its tight interaction with σ^A^~4~, it is plausible that WhiB1 could block Class II transcription activators and/or α~CTD~ from binding to σ^A^~4~, thus suppressing expression of genes regulated by these transcription activators and/or α~CTD~ if at high cellular levels (Figure [6D](#F6){ref-type="fig"}). We have experimentally demonstrated that WhiB1 can interact with σ^A^ to repress transcription from *rrnAP3 in vitro*. Moreover, it has been reported that under-expression of *whiB1* in *M. tuberculosis* caused more genes to be up-regulated than down-regulated (20 versus 3) in a comparative transcriptomic experiment ([@B8]). Our model is also consistent with the previous report that WhiB1 was post-translationally regulated by the Clp protease, and disruption of the WhiB1 degradation by the Clp protease inhibited cell growth in *M. tuberculosis* ([@B67]). On the other hand, our site-directed mutagenesis of *whiB1* in *M. smegmatis* suggests that the interaction with σ^A^~4~ is required for the essential role of WhiB1 in supporting mycobacterial growth. This may imply that the interaction between WhiB1 and σ^A^~4~ is required for the activation of essential genes, either alone or in concert with other regulators or α~CTD~ (Figure [6E](#F6){ref-type="fig"}). Candidate genes for this mode of regulation include the essential gene encoding salicylate synthase, *mbtI*, which was down-regulated with under-expression of WhiB1 in *M. tuberculosis* ([@B8],[@B68]).

Although the proposed working model of holo-WhiB1 is unprecedented among the σ^A^~4~--bound bacterial transcription factors, it closely resembles the mode of action of Spx, a global regulator that is responsive to heat and oxidative stress in *Bacillus subtilis* ([@B69]). Similar to holo-WhiB1, Spx is a monomeric transcription factor without known DNA binding capacity ([@B57]). It was first characterized as an anti-α factor because Spx was found to bind to α~CTD~ of RNAP and interfere with α~CTD~-dependent transcription of genes ([@B57],[@B72],[@B73]). Subsequently, it was reported that Spx also activate redox stress response genes and its interaction with α~CTD~ is required for transcription activation ([@B73],[@B74]). Like WhiB1, Spx is also regulated by the Clp protease ([@B75]), presumably to balance its dual activities.

In summary, our results indicate that holo-WhiB1 is a non-canonical transcription factor that interacts with σ^A^~4~ using a newly characterized interface dominated by hydrophobic contacts and represses transcription from *rrnAP3 in vitro*, distinguishing it from previously characterized σ^70^~4~-dependent transcription activators ([@B7],[@B11],[@B12]). The interaction with σ^A^~4~ also renders the Fe--S cluster in WhiB1 remarkably stable to O~2~, which is needed for NO sensing in aerobic bacteria. Future investigations of the genetic and functional aspects of WhiB1 and the structural characterization of WhiB1 interaction with the RNAP holoenzyme will further advance the mechanistic understanding of WhiB1 in NO sensing and transcriptional regulation in *M. tuberculosis*.
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